TLSA News

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Telia Lietuva results for 12 months of 2025

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial